Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Europe
  • Middle East & Africa
  • Asia Pacific
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Latin America | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Europe Middle East & Africa Asia Pacific
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latin America | es
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About
      • Board of Directors
        • Joerg Reinhardt
        • Simon Moroney
        • Nancy Andrews
        • Ton Buechner
        • Patrice Bula
        • Elizabeth Doherty
        • Ana de Pro Gonzalo
        • Bridgette Heller
        • Daniel Hochstrasser
        • Frans van Houten
        • Andreas von Planta
        • Charles Sawyers
        • William Winters
        • Charlotte Pamer-Wieser
      • Executive Committee
        • Vasant Narasimhan
        • Shreeram Aradhye, M.D.
        • James Bradner
        • Victor Bulto
        • Karen Hale
        • Harry Kirsch
        • Rob Kowalski
        • Steffen Lang
        • Klaus Moosmayer
        • Richard Saynor
        • Marie-France Tschudin
        • Lutz Hegemann
        • Michael Willi
        • Kees Roks
      • Strategy
        • People and Culture
        • Data and Digital
      • Products
      • Innovative Medicines
      • Sandoz
      • Operations
        • Global Biotech Cooperations
      • Diversity & Inclusion
        • Equity
        • Diversity & Inclusion Governance and Community
        • Inclusivity
        • Parental Leave
        • Society
      • Quality
        • Audit program
        • Novartis Quality Management System (QMS)
        • Product and patient safety training
        • Regulatory inspections
        • Product recalls
        • Third-party suppliers
      About Novartis
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Diseases
      • Patient Organization Funding
      • Adverse Event Reporting
      • COVID-19: Patients and Caregivers
      • Stories: Patients Perspectives
      Patients & Caregivers
    • Healthcare Professionals
      • Medical Congresses and Events
        • Abstract summaries for EULAR
        • Abstract summaries for ACR
        • Abstract summaries for EADV
      • Products
      • Novartis Pipeline
      • Managed Access Programs
        • Novartis Gene Therapies Managed Access Program
      • Novartis External Funding
      • Healthcare Professional Resources by Country
      • Investigator-Initiated Trials / Studies
      • Transparency and Disclosure
      Healthcare Professionals
    • Research & Development
      • Novartis Institutes for BioMedical Research
        • Collaborations
        • NIBR Global Scholars Program
      • Technology Platforms
        • Radioligand Therapy
        • Gene Therapy
        • Cell Therapy
      • Research Disease Areas
        • Immuno-oncology research at Novartis
        • Oncology research at Novartis
        • Cardiovascular and metabolic disease research at Novartis
        • Autoimmunity, transplantation and inflammatory disease research at Novartis
        • Ophthalmology research at Novartis
        • Neuroscience Research at Novartis
        • Musculoskeletal Disease Research at Novartis
        • DAx: exploratory disease research at Novartis
      • Research Locations
        • Novartis Institute for Tropical Diseases
      • Novartis Pipeline
      • Translational Medicine
      • Research & Development Approach
      • Stories from our Labs
      • Open Source Science
      Research & Development
    • ESG
      • Access
        • Creating sustainable business models
        • Value-Based Pricing
        • Sub-Saharan Africa
        • Donations
        • Novartis Access Principles
        • Novartis Oncology Access
        • Patents and Licensing
      • Ethics, Risk and Compliance
        • Ethical Behavior
        • Compliance
        • Human Rights
        • Learning and Engagement
        • Risk management
      • Environmental Sustainability
        • Climate
        • Waste
        • Water
      • Global Health
        • Anti-Microbial Resistance (AMR)
        • Avoidable Blindness
        • Chagas Disease
        • Leprosy
        • Malaria
        • Sickle Cell Disease (SCD)
        • Novartis Foundation
      • Diversity & Inclusion
      • Reporting
        • Environmental, Social and Governance (ESG) Index
        • ESG Rating Performance
        • Codes, Policies and Guidelines
        • Materiality Assessment
        • Transparency and Disclosure
        • Targets
        • Positions
      Environmental, Social and Governance
    • Investors
      • Event Calendar
      • Financial Data
        • Novartis Annual Results
        • Novartis Quarterly Results
        • Novartis SEC Filings
        • Product Sales
        • Fixed-Income Securities
        • Expected Currency Impact
      • Share Data & Analysis
        • Share Monitor
        • Dividend Information
        • Share Ownership
        • Share Overview
      • Shareholder Information
        • General Meetings
        • American Depository Receipts (ADR)
        • Share Buy-Back
        • Frequently Asked Questions
      • Company Overview
        • Corporate Governance
      • Novartis Annual Reporting Suite
        • Reporting Archive
        • Publications Order Form
      • ESG
      Investors
    • News
      • News Archive
      • Media Library
      • Stories
      • Subscribe
      News
    • Careers
      • Career Search
      • Our Teams
        • Careers in Commercial
        • Careers in Communications and Advocacy
        • Careers in Consulting
        • Careers in Digital
        • Careers in Health, Safety & Environment
        • Careers in Information Technology (IT)
        • Careers in Medical & Development
        • Careers in People & Organization
        • Careers in Procurement
        • Careers in Research
        • Careers in Strategy
        • Careers in Manufacturing and Supply
        • Ethics, Risk & Compliance (ERC)
        • Careers in Legal
      • Career Programs
        • Community Exploration & Learning Lab (CELL)
      • Early Talent
      • Postdoc Program
        • Andreas Bender, PhD
        • Boxun Lu, PhD
        • The Novartis Innovation Postdoctoral Fellowship
        • The Novartis Discovery Postdoctoral Fellowship
        • Postdoc Research Themes
        • Recognition
        • Postdoc Program Leadership
      • International Careers
      • Learning and Development
      • Well-being
      • Internship Programs
      Careers
    • COVID-19 Information Center
      COVID-19 Novartis response
    • Clinical Trials
      Clinical Trials
    • Partnering
      Partnering
    • Contacts
      Contacts
    Home

Stories

Story Navigation
  • All Topics
  • Discovery
  • From Our Labs
  • Patient Perspectives
  • Access to Healthcare
  • People & Culture
icon
  • From Our Labs
    Biomedical ResearchDrug DiscoveryNovartis Institutes for BioMedical ResearchReimagine MedicineNew Scientific Discoveries
    Jul 19, 2021
    Molecular glue kills cancer cells in mice

    Compounds block a protein involved in many cancers by cementing it shut.

    From Our Labs
  • From Our Labs
    Biomedical ResearchDigitalDrug DiscoveryNovartis Institutes for BioMedical ResearchPostdoc ProgramDrug Design
    Jul 20, 2021
    Tuning drugs to succeed on the cell’s surface

    Researchers improve our understanding about how compounds bind to proteins in the cell membrane—and the membrane itself.

    From Our Labs
  • From Our Labs
    Biomedical ResearchNovartis Institutes for BioMedical ResearchPostdoc ProgramScientific Discoveries
    Jul 19, 2021
    Building brain organoids to shed light on disease

    Three-dimensional clusters of human neurons could allow scientists to watch neurological diseases develop in the lab.

    From Our Labs
  • From Our Labs
    Biomedical ResearchMedical InnovationsNovartis Institutes for BioMedical ResearchPostdoc Program
    Jul 19, 2021
    With a "brain in a dish," researchers take on neurological disorders

    Neurological diseases develop out of sight. Novartis neuroscientists are bringing them into the light, using human brain cells grown in the lab.

    From Our Labs
  • From Our Labs
    Biomedical ResearchGene SequencingNovartis Institutes for BioMedical ResearchReimagine MedicineNext Generation SequencingGenetic Disease
    Jul 19, 2021
    Electrical brainstorms traced to genetic mutations

    Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.

    From Our Labs
  • From Our Labs
    Novartis Institutes for BioMedical ResearchNew Scientific DiscoveriesScientific ResearchGenetic Disease
    Jul 19, 2021
    Eye disease tracked to a glitch in starburst cells

    A cellular computing error wreaks havoc on vision.

    From Our Labs
  • From Our Labs
    Biomedical ResearchDrug DiscoveryNovartis Institutes for BioMedical ResearchReimagine MedicineNew Scientific DiscoveriesScientific Research
    Jul 19, 2021
    Hooked on science, Jay Bradner becomes top researcher at Novartis

    New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.

    From Our Labs
  • From Our Labs
    Biomedical ResearchDrug DiscoveryNeuroscienceNovartis Institutes for BioMedical ResearchPostdoc ProgramGenetic Disease
    Jul 20, 2021
    When tiny brains are best for brain research

    Zebrafish imaging sheds light on human neurological conditions.

    From Our Labs
  • From Our Labs
    Drug DiscoveryNovartis Institutes for BioMedical ResearchPostdoc ProgramScientific ResearchCareersClinical Trials
    Jul 19, 2021
    5 tips for making smart decisions on research projects

    Make smart decisions about your research projects.

    From Our Labs
  • From Our Labs
    Novartis Institutes for BioMedical ResearchReimagine MedicineCancer Research Institute
    Jul 19, 2021
    CRISPR genome editing fuels cancer drug discovery

    Genome editing advances drug discovery in biomedical research.

    From Our Labs
  • From Our Labs
    Drug DiscoveryGene SequencingNovartis Institutes for BioMedical ResearchClinical ResearchBiomedical JobsDrug Design
    Jul 20, 2021
    Rediscovering the power of nature’s exquisite complexity

    Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research

    From Our Labs
  • From Our Labs
    Drug DiscoveryNovartis Institutes for BioMedical ResearchTropical DiseasesClinical ResearchBiomedical JobsEye Disorders
    Jul 20, 2021
    Opening chemistry education to the world

    Novartis taps MOOC technology to share chemistry education with the world

    From Our Labs

Pagination

  • ‹ Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • › Next page

Novartis

Navigate
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • COVID-19 Info Center
  • ESG
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2022 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience